K2 Biolabs
Houston, US · Founded 2021 · Delaware corporation · 15 employees on LinkedIn · 1 known investors
Find your way into K2 Biolabs
K2bio operates a fully equipped, AAALAC-accredited contract vivarium facility in Houston supporting preclinical research for biotechnology and pharmaceutical companies. The facility provides flexible access to animal housing, technical services, imaging systems, and expertise across multiple therapeutic modalities including biologics, small molecules, and cell therapies.
Founders & leadership
Board
KS
AD
Andrew DeSommaMember of the Board of Directors
GF
Gerard FleuryMember of the Board of Directors
CJ
Clifford J. StocksMember of the Board of Directors
AS
Andrew StrongCo-Founder and Board Chair
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.1M disclosed across 2 rounds · 2021–2023
▶$615.5KraisedAug 2023 · 7 investors · BiotechnologyRule 506(b)
▶$615.5KraisedAug 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew DeSommaDirector
- Gerard FleuryDirector
- Clifford J. StocksDirector
- Andrew StrongDirector
- Daniel ClarkExecutive Officer
- Kevin SlawinDirector
- Kieron JonesDirector, Executive Officer
- Offering amount
- $3M
- Amount sold
- $615.5K
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$5.5MraisedMar 2021 · 40 investors · BiotechnologyRule 506(b)
▶$5.5MraisedMar 2021 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- KIERON JONESExecutive Officer, Director
- Andrew StrongDirector
- Andrew DeSommaDirector
- Kevin SlawinDirector
- Clifford StocksDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- Minimum investment
- $25K
- Proceeds to insiders
- $270K
- First sale
- Mar 2021
- Incorporated
- Limited Liability Company, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
bio19 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
KALA BIO15 shared keywordsA biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
Krystalbio13 shared keywordsKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
Coya Therapeutics13 shared keywordsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
Korro Bio12 shared keywordsKorro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.
Companies competing with K2 Biolabs for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does K2 Biolabs do?
- K2bio operates a fully equipped, AAALAC-accredited contract vivarium facility in Houston supporting preclinical research for biotechnology and pharmaceutical companies. The facility provides flexible access to animal housing, technical services, imaging systems, and expertise across multiple therapeutic modalities including biologics, small molecules, and cell therapies.
- Who are K2 Biolabs's investors?
- K2 Biolabs's investors include Rapha Capital Management, LLC.
- How much funding has K2 Biolabs raised?
- K2 Biolabs has disclosed $6.1M raised across 2 rounds.
- Where is K2 Biolabs headquartered?
- K2 Biolabs is headquartered in Houston, US.